Antibiotics and irritable bowel syndrome: when the treatment becomes a trigger
Antibiotics raise the risk of IBS by nearly 70%. Understanding why can help you better protect your gut microbiome.
Published on
When a common medicine leaves a lasting mark
You took antibiotics a few weeks ago, and since then your gut hasn't been the same. Bloating, pain, unpredictable bowel habits… This scenario is far from unusual. Robust scientific evidence now establishes a clear link between antibiotic use and the onset of irritable bowel syndrome (IBS). This is no coincidence, and understanding the mechanisms at play can change the way you approach both your treatment and your recovery.
A risk increased by 69 to 80%
The figures speak for themselves: according to a recent meta-analysis, taking antibiotics in the context of infectious enteritis multiplies the risk of developing IBS by 1.69 (odds ratio, 95% CI: 1.20–2.37). A longitudinal study by Krogsgaard et al. confirms this trend with an odds ratio of 1.8.
Certain classes of antibiotics appear to be particularly implicated. A retrospective study involving more than 26,000 patients found a strong association between exposure to macrolides and tetracyclines and the subsequent development of IBS. Not all antibiotics are equal in this regard — and the nature of the treatment received matters.
The microbiome: the main collateral victim
To understand why antibiotics can trigger IBS, we need to look at what happens inside the gut during — and after — the course of treatment.
Our digestive tract is home to approximately 38 trillion bacteria, forming a complex and finely balanced ecosystem: the gut microbiome. Antibiotics, in targeting pathogenic bacteria, do not always distinguish between harmful and beneficial strains. The result is dysbiosis — a profound disruption of this ecosystem.
This disruption bears a striking resemblance to what is observed in patients with IBS:
- Loss of bacterial diversity
- Proliferation of Enterobacteriaceae (E. coli, Klebsiella, Shigella), bacteria with pro-inflammatory properties
- Impairment of the microbiome's metabolic functions
These pro-inflammatory bacteria contribute to low-grade inflammation in the gut wall — a central mechanism in the pathophysiology of IBS.
What makes matters worse is that this disruption is not always short-lived. A Swedish study published in Nature Medicine found that the composition of the microbiome can remain altered 4 to 8 years after a course of antibiotics, or even longer. A few days of treatment can therefore leave a lasting biological imprint.
Post-infectious IBS: a particularly high-risk context
IBS frequently develops in the wake of acute infectious gastroenteritis. A meta-analysis of nine prospective studies reports an odds ratio of 5.9 for the development of IBS following a gut infection. In this context, antibiotics prescribed to treat the infection themselves become an additional aggravating factor.
An intestinal tract already weakened by infection then has its microbiome disrupted twice over: first by the pathogens, then by the antibiotic treatment. This combination creates particularly fertile ground for chronic IBS to take hold.
How to protect your microbiome
This does not mean refusing antibiotics when they are genuinely needed — they remain essential, and sometimes life-saving, medicines. However, several strategies can help limit their impact on the microbiome:
- Avoid self-medicating with antibiotics: antibiotics have no effect on viral infections (colds, flu). Reserving them for confirmed bacterial infections means not disrupting your microbiome unnecessarily.
- Do not stop your course early: stopping an antibiotic as soon as you feel better can encourage bacterial resistance and relapse. Always complete the prescribed duration.
- Support your microbiome during and after treatment through:
- Fermentable fibre (pulses, root vegetables, oats), which feeds beneficial bacteria and supports their recovery
- Prebiotics such as xanthan gum, which stimulate the production of short-chain fatty acids (SCFAs), essential for the health of the gut lining
- Targeted probiotics: the yeast Saccharomyces boulardii CNCM I-745 and the bacterium Lacticaseibacillus rhamnosus GG show promising results in limiting antibiotic-associated dysbiosis and diarrhoea
- Reduce foods high in saturated fats and simple sugars, which encourage the proliferation of harmful microbes at the expense of beneficial bacteria
A therapeutic paradox worth knowing about
The relationship between antibiotics and IBS contains a notable irony: certain narrow-spectrum antibiotics, such as rifaximin, are used precisely to treat IBS — particularly forms with predominant diarrhoea and significant bloating. Studies show that rifaximin is more effective than placebo at improving overall symptoms (OR = 1.57) and reducing bloating (OR = 1.55).
This paradox illustrates just how much the bacterial target and the chosen antibiotic class can make all the difference.
Key takeaways
Antibiotics are a major — though not exclusive — trigger of IBS. The dysbiosis they induce creates favourable conditions for chronic intestinal inflammation and visceral sensitisation, two central pillars of IBS. By taking a considered approach to antibiotic use and actively supporting your microbiome before, during, and after treatment, it is possible to significantly reduce this risk.
Your gut has a long memory — and your microbiome deserves to be looked after, even when you are treating something else entirely.